Rapid Uptake Products
To support stronger adoption and spread of proven innovations.
The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date. The 2020/22 programme builds on the successes of the 2019/20 RUPs programme, with themes selected via an open, staged, selection process.
The following additional innovations will be supported through the Rapid Uptake Products (RUP) Programme for 2020/22:
Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors: The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20). Find out more here.
For more information on this product, please contact Dr Dai Roberts, Senior Programme Development Lead at Health Innovation Manchester, or Nadine Thomas, Programme Development Lead at Health Innovaton Manchester.
Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath: FeNO testing is a method of diagnosing asthma by measuring fractional exhaled nitric oxide (FeNO) in the breath of patients suspected of having asthma. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma. Find out more here.
Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab: Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma. Find out more here.
For more information on the FeNo and Asthma products, please contact: Cath Barrow, Senior Programme Development Lead at Health Innovation Manchester or Joy Stonebanks, Programme Development Lead at Health Innovation Manchester.